Iterate is an ecosystem for digital innovation, and we like to describe ourselves as a company that builds companies. We contribute from A-Z when building, starting with creating concepts based on key insights to launching and improving products whilst living in the marketplace. We find the right team and work toward the company culture that enables us to deliver value to our customers quickly. The key to achieving this is reinvesting all our profits in the ideas of our employees, or selected entrepreneurs. Five years into this strategy, we own shares in fifteen ventures; all of which are showing promising results. Our 70 designers, developers, and product managers just moved into new locations in the center of Oslo. 
Close collaboration with our customers is key to our success. They provide domain know-how, and we provide tools, strategies, and experts. Together we uncover the best way that connects your strategy and idea with the market needs. Our goal is to achieve minimum risk and give our customers the best possible starting point for scaling, on their own, or in continued collaboration.

What is Between? The process of moving out of your home and into a new one can be one of the greatest stresses of life. To the average person, it’s an expensive and overwhelming process that involves listmaking, phone calls with real estate agents, taking time off from work, packing, heavy lifting, buying takeaway dinners, cleaning, and so on. Have you ever wondered why there’s no app that could help alleviate the pain points of moving? We have. That’s why we founded Between – Norway’s first moving platform. Between is a digital service that revolutionizes the moving process with technology, innovation and the ability to understand needs. To the average person, it means less stress and more control. To electrical and insurance companies, who each year lose thousands of customers due to address changes, it will lead to a lower churn rate and a higher return on investment. To real estate agents and developers, we will provide added value to a much smoother customer journey. What we have achieved We are a small group of entrepreneurs who have founded several successful businesses together. One of which is an online change of address service, a pilot company which has helped us research the moving market for the last two years – with over 50.000 registered customers in Norway and Sweden. Between is the next step. Not just for us, but for the millions of people out there who are about to begin a new life in a new home. We’re doing this because we know that if we can make moving easier, we will also make life easier.

Moderne Media ble startet med et ønske om å formidle gode historier. Det er fortsatt kjerneverdien i alt vi gjør. Med podkast, TV, film, reklame og sosiale medier, har vi flere muligheter enn noen gang til å produsere og dele gode historier.Folkene du møter i Moderne Media jobber med det de synes er morsomst, og det de er flinkest til. Vi har oppdaget at de to tingene har en sammenheng. Derfor prøver vi å rendyrke personligheter og individer.

Fagweb AS jobber med utvikling av nettkonsepter med alt som hører til – kode, tekst, analyse og annonse. Fagweb jobber i hovedsak med egne konsepter slik som Dinero.no. Vi er også involvert i prosjekter som Lappeliten.no.Dinero.no: Dinero.no er en forbrukerportal med spesielt fokus på privatøkonomi. Vi har de siste årene vokst kraftig, og er etterhvert en mye brukt portal og en ofte sitert kilde i andre norske medier.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

Preventing One Million Falls Before 2024 Dele Health Tech is redefining how the market conceptualizes and achieves fall prevention by offering a data fusion platform that functions as middleware between hardware and data stream partners. Our mission: To save lives through fall prevention, and prevent one million falls by 2024.

Nordic Electrofuel offers a solution for the rapid transition from fossil to renewable electrical energy for all transport sectors. It is based on the conversion of renewable electric energy into liquid electro-fuels that can be as easily transported, stored, and used as conventional fossil hydrocarbons. It also provides a good solution to distribute and store stranded electrical energy. PTL (Power To Liquid) has been considered too expensive, but with the low electricity price in Norway and new efficient processing and upgrading solutions, it has become commercially feasible. Electrification of transportation is required to avoid catastrophic climate change. Battery- or cable-electric solutions are not feasible for transport like aviation and long-distance marine transport. Liquid energy carriers such as biofuels are desperately needed but limited. The fuel is free of sulfur and can therefore be used maritime industry as a fuel after 2022. The fuel emits much fewer particles and aromatics than conventional fossil fuel, so it also solves the local pollution problem. Competitive advantages: • Norway’s low electricity price from hydro and lately also wind power. • 20 - 30 % lower electricity consumption than with existing technology • Lower production price than advanced biofuels • Agreements in place for a site at Herøya, which has all utilities (cooling water, cheap renewable electricity, etc.) and processing expertise available. • About the same source to shaft efficiency as hydrogen, but with much lower total CAPEX due to no investment in distribution systems and engines.

Norwegian Oil & Gas Company was founded in 2016. Nor Oil Tools provide innovative tools to both simplify operations and cut costs without changing your whole process. Allowing you to cut your pipes, reduce your costs and improve your HSE. The Nor Tubular Cutter (NTC 325-10S) is the first tool to be released by Noroiltools and was launched in late 2017.

A bio-and medtech Company developing and selling proprietary solutions for using oxygen in various applications. Currently focussing on beverages (water, sports- and isotonic drinks), wound healing, cosmetics and fish farming. Licensing platform technology for applying oxygent to other products. Oxy Solutions is a privately held Norwegian based biotech company that has developed and patented an innovative technology for highly oxygenating liquid. Oxy Solutions'​ core business and strategy is to develop, document, IP protect, and commercialize the technology primarily within wound healing. The company has an in-house R&D facility in Norway. The company has funding from the Norwegian Research Council. Oxy Solutions is in possession of patented technology that makes it possible to greatly increase the dissolved level of oxygen in water. Tests have indicated stable levels in excess of 70 mg/l, or approximately 10 times higher than previously thought possible.

- an easy-to-use all-in-one solution for the HORECA industry- GastroPlanner is one of Norway's leading suppliers of online tools for HORECA (hotels, restaurants, and catering). We offer a complete platform with all the tools and integrations needed to improve and streamline the daily operation of a HORECA business.

BxSoftware ble stiftet i 2011, etter at programvare hadde blitt et stadig viktigere produktområde for Barex Distribution og BarCom Labelling. Barex og BarCom har lenge levert egen programvare som et tilleggsprodukt til håndterminaler, men fra 2011 har programvaren fått mer fokus og blir solgt som et selvstendig produkt via BxSoftware. Vårt søsterselskap Barex Distribution har i 2015 blitt kjøpt opp av EET Europarts, som har blitt vår nye hoveddistributør av vår programvare. Vi har som mål å være markedsledende på innovasjon og kostnadseffektive løsninger for logistikk og datafangst. BxSoftware selger standardiserte produkter via et bredt forhandlernett, men leverer også tilpasninger og spesielt utviklede løsninger til bl.a. prosess-industri og lagerautomasjon, der vi får utnyttet vår kompetanse på logistikk, integrasjon og datafangst.

Subjekt er Norges raskest voksende kulturavis. Vi skal være landets ledende kulturavis og din beste venn i spørsmål om god smak. Vi publiserer nyheter, debattstoff, anmeldelser, featureartikler, kritikk og underholdning av og for en ung voksen, urban og kulturinteressert målgruppe. Dekningsområdet er kunst, kultur og samfunn i hele Norge. Ansvarlig redaktør er Danby Choi, som i 2020 ble nominert til Årets nyskaper av Oslo redaktørforening. Mer info: https://subjekt.no/om-subjekt

Our Values: -Help move money to companies that make a positive difference on our climate, human rights, and planet. -Create a citizen-powered investment movement for good We do this by: -Providing an all-in one research tool to support values-based investing. We want the public and investors to have access to knowledge of corporate performance on human rights and sustainability so they put their dollars into companies that align with their values of positive social and environmental impact. Together, we make a difference and invest in what matters.

Romly aims to lead the charge into the future of the real estate industry by collecting, maintaining and distributing basic building data in open 3D formats. We construct digital twins of all kinds of buildings, our unique approach allows us to give all properties the benefits of an updated digital twin. We have experienced great interest for our ideas, and we are looking for talent to join our team, so get in touch if you want to take part in shaping the data driven future of real estate!

Oslo-based Epigram specialises in computer vision and visual classification, developing cutting edge tools and software to collect and analyse big data, with an acute focus on the application of AI to understand content. The company, founded in 2017, worked with multiple clients, including Huddly, Gjensidige, Tradono, and No Isolation to develop bespoke artificial intelligence and machine learning solutions.